There is huge upward potential in the stock pick of unknown billionaire Phil Gross

We recently released a list 10 stocks of unknown billionaire Phil Gross with huge upward potential. In this article, we will explore Janux Therapeutics, Inc. (NASDAQ: JANX) A stock pick with other unknown billionaire Phil Gross has huge upside potential.

Phillip "Phil" Gross is an experienced investor and influential figure who is co-founder, managing director, managing director and healthcare portfolio manager of Adage Capital Management. Robert Atchinson is his longtime collaborator and co-founder Robert Atchinson as the company’s portfolio manager, while Gross’s leadership and strategic vision plays a foundation in shaping Adage’s long-term investment philosophy and reputation. The two worked as donation analysts at Harvard University in the mid-1980s. Their professional synergy led them to leave Harvard Management in the 1990s after conducting a public review of performance-based bonuses. With Harvard’s initial $1.8 billion investment backed and a deal to acquire 10% of the company’s revenue for the university, they launched Adage Capital Management in 2001 with a team of 18 people.

Under Gross's co-led leadership, Adage has become a key player in client management assets in prestigious institutions such as Harvard, Dartmouth College, Northwestern University, the American Red Cross and the Getty Foundation. The company specializes in long/short equity strategies guided by fundamental analysis and conducts risk arbitrage and event-driven opportunities when market conditions are favorable. Adage Capital Management and its predecessor, Harvard Management, featured equity group, has consistently surpassed the broader market benchmark by 3.5% over the past 15 years. This proves that GROSS helps instill disciplines in a research-driven investment framework.

Gross himself has brought a deep background to healthcare investment, serving at Harvard Management for nearly two decades, holding various positions including healthcare and retail analysts, equity research director and partner. His academic certificates include Bachelor of Finance and Economics from the University of Wisconsin (1982) and MS from Investments (1983). He is still actively interacting with his alma mater and serves on the advisory board of Steve Hawk Applied Securities Analysis Center and Nicholas Applied Companies Financing Center. In recognition of his professional achievements and continued contribution, Gross received the Distinguished Alumni Award from the University of Wisconsin Business School in 2006.

Beyond finance, Gross is a determined philanthropist. He co-founded the Strategic Grant Partner, an organization dedicated to driving systemic changes in education and family services throughout Massachusetts. He also serves as Vice President of the Board of Directors of Youth Enrichment Services, a nonprofit organization that provides outdoor entertainment experiences for urban youth. Additionally, he holds a board position with the American Skiing and Skiing Association, where he serves as Vice Chairman of the Investment Committee and a board position with the T2 Foundation.

Adage Capital Management reported $57.19 billion in custodial securities for the latest 13F filings filed in Q4 2024, with the top ten holdings accounting for 31.7% of the total portfolio portfolio, indicating a strategic but diversified approach to asset allocation. Although Atchinson oversees day-to-day portfolio management, Gross's enduring influence and expertise, especially in healthcare investment, continues to shape the company's long-term success and institutional credibility.

We searched Adage Capital Management's 4th quarter 2024 13F file to identify the stock picks of unknown billionaire Phil Gross with the highest upside potential. At the time of writing, we compiled stocks with upside potential above 34%, and discussed why they are powerful potential investments. Finally, we rank stocks according to the rising order of their upward potential. To help readers provide more environments, we use data from 1,009 hedge funds tracked in the fourth quarter of 2024 with Insider Monkey refer to hedge fund sentiment around each stock.

Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our quarterly newsletter strategy selects 14 small and large stocks every quarter, returning 363.5% since May 2014, exceeding 208 percentage points (See more details here).

Janux Therapeutics, Inc. (Janx): There is huge upward potential in the stock draft of unknown billionaire Phil Gross

While the researchers analyzed the data, they stirred a bunch of test tubes and beakers in the lab.

Number of hedge fund holders as of the fourth quarter

Adage Capital Management's Equity shares: $163.93 million

As of May 2: 189.86% upward potential

Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical company committed to promoting innovative immunotherapies designed to produce tumor-specific immune responses. The company focuses on therapies that target and destroy cancer cells while retaining healthy tissue, thus minimizing adverse reactions associated with traditional cancer treatments.

Financially speaking, Janux Therapeutics, Inc. (NASDAQ: JANX) showed strong capital status by the end of 2024. As of December 31, the company reported $1.03 billion in cash, cash equivalent investment and short-term investment, a significant increase of $344 million, and this huge effort has continued Janux's efforts in financial reserve work since the end of 2023. The company's R&D expenses rose to $20.8 million in the fourth quarter, totaling $68.4 million that year, while $12.2 million and $54.9 million in the same period in 2023 reflect the intensification of clinical activity in its pipeline. Similarly, general and administrative expenses for the quarter increased to $8.2 million for the quarter, and $4.1 million for the full year, up from $6.4 million and $26.1 million for the previous year as the company expanded its operating infrastructure to support clinical development and long-term growth.

Despite the increase in spending, Janux Therapeutics, Inc. (NASDAQ: JANX) reported a net loss of $20.2 million in the fourth quarter, a net loss of $690 million for the full year of 2024, compared with a net loss of $11.8 million in 2023, compared with a net loss of $11.8 million in 2023, and a net loss of $58.3 million in 2023, which are consistent in the clinical development stage. The increased losses correspond to the company's strategic improvements in treatment planning and development pipelines. Janux remains fully vibrant and is committed to advancing its mission to provide translational immunotherapy to leverage tumor-specific biology to combat cancer safely and effectively.

In the fourth quarter of 2024, Adage Capital Management significantly increased its use of Janux Therapeutics, Inc. (NASDAQ: JANX) investments have raised its position to more than 3 million shares, up 48% from 2.08 million shares in the previous quarter. The expansion brings the fund's total stake in the company to an estimated $1.6 billion.

Overall, Janx Ranked first There is huge upside potential in the stock picks of our unknown billionaire Phil Gross. While we acknowledge the potential of JANX is an investment, our belief is that AI stocks provide higher returns and do this in a shorter time. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for AI stocks that are more promising than Janx but have less than 5 times its earnings, check out our report Cheapest AI stocks.

Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.

Disclosure: None. This article was originally published in Internal monkey.